This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tao, Y.-X. Articles by Segaloff, D. L. Search for Related Content PubMed PubMed Citation Articles by Tao, Y.-X. Articles by Segaloff, D. L.

Constitutive Activation of G Protein-Coupled Receptors as a Result of Selective Substitution of a Conserved Leucine Residue in Transmembrane Helix III

Departments of Physiology and Biophysics (Y.-X.T., A.N.A., X.L., D.L.S.) and Pharmacology (K.N.) The University of Iowa Iowa City, Iowa 52242

Whereas numerous mutations of the human lutropin receptor (hLHR) and human TSH receptor (hTSHR) have been shown to cause constitutive activation of these receptors, it has been suggested that either the hFSHR as a whole, or the i3/TM VI region of the hFSHR, is less susceptible to mutation-induced constitutive activation. However, as shown herein, substitution of a highly conserved leucine residue in transmembrane III (TM III) of the hFSHR (Leu III.18) with arginine causes a 5-fold increase in basal cAMP in transfected cells, consistent with a strong constitutive activation of the hFSHR. Interestingly, this mutant is unresponsive to further hormonal stimulation. Substitutions of hFSHR(L460) with lysine, alanine, or aspartate show that only arginine causes constitutive activation. However, all result in decreased FSH responsiveness, suggesting a role for L460 in FSH-stimulated cAMP production by the hFSHR.

Because Leu III.18 is highly conserved in rhodopsin-like G protein-coupled receptors (GPCRs), we tested the effects of substitution of the comparable leucine in the human ß₂-adrenergic receptor (hß₂-AR). Substitution of L124 in the hß₂-AR with arginine, lysine, or alanine resulted in constitutive activation as evidenced by increased basal levels of cAMP that could be attenuated by an inverse agonist. In all cases, isoproterenol-stimulated cAMP was unaffected.

Taken altogether, our data support a model whereby Leu III.18 may play a general role in GPCRs by stabilizing them in an inactive state. Constitutive activation may arise by both a disruption of Leu III.18 as well as the introduction of a specific residue that serves to stabilize the active state of the receptor.

This article has been cited by other articles:

				D. M. Rosenbaum, V. Cherezov, M. A. Hanson, S. G. F. Rasmussen, F. S. Thian, T. S. Kobilka, H.-J. Choi, X.-J. Yao, W. I. Weis, R. C. Stevens, et al. GPCR Engineering Yields High-Resolution Structural Insights into 2-Adrenergic Receptor Function Science, November 23, 2007; 318(5854): 1266 - 1273. [Abstract] [Full Text] [PDF]

				M. Zhang, Y.-X. Tao, G. L. Ryan, X. Feng, F. Fanelli, and D. L. Segaloff Intrinsic Differences in the Response of the Human Lutropin Receptor Versus the Human Follitropin Receptor to Activating Mutations J. Biol. Chem., August 31, 2007; 282(35): 25527 - 25539. [Abstract] [Full Text] [PDF]

				U. Ringkananont, J. Van Durme, L. Montanelli, F. Ugrasbul, Y. M. Yu, R. E. Weiss, S. Refetoff, and H. Grasberger Repulsive Separation of the Cytoplasmic Ends of Transmembrane Helices 3 and 6 Is Linked to Receptor Activation in a Novel Thyrotropin Receptor Mutant (M626I) Mol. Endocrinol., April 1, 2006; 20(4): 893 - 903. [Abstract] [Full Text] [PDF]

				A. P N Themmen An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms Reproduction, September 1, 2005; 130(3): 263 - 274. [Abstract] [Full Text] [PDF]

				Z.-L. Lu, R. Gallagher, R. Sellar, M. Coetsee, and R. P. Millar Mutations Remote from the Human Gonadotropin-releasing Hormone (GnRH) Receptor-binding Sites Specifically Increase Binding Affinity for GnRH II but Not GnRH I: EVIDENCE FOR LIGAND-SELECTIVE, RECEPTOR-ACTIVE CONFORMATIONS J. Biol. Chem., August 19, 2005; 280(33): 29796 - 29803. [Abstract] [Full Text] [PDF]

				H. Shinozaki, V. Butnev, Y.-X. Tao, K. L. Ang, M. Conti, and D. L. Segaloff Desensitization of Gs-Coupled Receptor Signaling by Constitutively Active Mutants of the Human Lutropin/Choriogonadotropin Receptor J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1194 - 1204. [Abstract] [Full Text] [PDF]

				O. Larsson, D. Thormeyer, A. Asinger, B. Wihlen, C. Wahlestedt, and Z. Liang Quantitative codon optimisation of DNA libraries encoding sub-random peptides: design and characterisation of a novel library encoding transmembrane domain peptides Nucleic Acids Res., December 1, 2002; 30(23): e133 - e133. [Abstract] [Full Text] [PDF]

				C. Prioleau, I. Visiers, B. J. Ebersole, H. Weinstein, and S. C. Sealfon Conserved Helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor. IDENTIFICATION OF A NOVEL "LOCKED-ON" PHENOTYPE AND DOUBLE REVERTANT MUTATIONS J. Biol. Chem., September 20, 2002; 277(39): 36577 - 36584. [Abstract] [Full Text] [PDF]

				W.-b. Zhang, J.-M. Navenot, B. Haribabu, H. Tamamura, K. Hiramatu, A. Omagari, G. Pei, J. P. Manfredi, N. Fujii, J. R. Broach, et al. A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists J. Biol. Chem., June 28, 2002; 277(27): 24515 - 24521. [Abstract] [Full Text] [PDF]

				M. Ascoli, F. Fanelli, and D. L. Segaloff The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective Endocr. Rev., April 1, 2002; 23(2): 141 - 174. [Abstract] [Full Text] [PDF]

				H. Shinozaki, F. Fanelli, X. Liu, J. Jaquette, K. Nakamura, and D. L. Segaloff Pleiotropic Effects of Substitutions of a Highly Conserved Leucine in Transmembrane Helix III of the Human Lutropin/Choriogonadotropin Receptor with Respect to Constitutive Activation and Hormone Responsiveness Mol. Endocrinol., June 1, 2001; 15(6): 972 - 984. [Abstract] [Full Text] [PDF]